Value of Regulatory T Cell in Hepatocellular Carcinoma Patients | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 95, Volume 85, Issue 1, October 2021, Page 3228-3235 PDF (1.06 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2021.196476 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Maher Borai Mohammad; Seham Mahrous Zaki Nasr; Afifi Fahmy Afifi Ahmed; Neveen Emam- Eldein | ||||
| Departments of 1Clinical Pathology Faculty of Medicine, Zagazig University, Egypt | ||||
| Abstract | ||||
| Background: Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver, representing the second leading cause of cancer-related death worldwide. It is the 2nd leading cause of cancer death in men and the sixth among women. Objectives: To investigate the role of CD4+, CD25+, FOXp3+Regulatory T cells (Tregs) in patients with HCC and their correlation with the prognosis. Patients and Methods: The study was conducted on 25 patients with hepatocellular carcinoma. Detection of regulatory T cells by flow cytometry using CD4, CD25 and FOXp3 before and after intervention. Results: CD4 significantly increased but CD4/CD25, Foxp3, AFP, ALT and AST significantly decreased. Patients with high numbers of FOXp3+ cells and those with higher FOXp3+ Tregs /CD4+ T cell ratio had poorer overall survival rates. Conclusion: Tregs seem to be a promising prognostic factor in patients with HCC and a high Tregs level has been reported to be correlated with poor outcomes in a number of publications. | ||||
| Keywords | ||||
| HCC; CD4; FOXP3; CD25 | ||||
|
Statistics Article View: 136 PDF Download: 240 |
||||
